Eli Lilly and Company · Gene Therapy · Phase 2
ActiveTherapeuticStronger sources
Population
Children & adults · Cohort-specific; no overall age limit
Biallelic OTOF profound bilateral auditory neuropathy
Evidence
trial
Confidence
95%
Indications
Hearing LossSensorineural Hearing LossGenetic Hearing LossOTOF-Related Hearing Loss
